GlySure’s in-hospital continuous blood glucose monitoring systems may help cut down on blood-sampling frequency while allowing giving earlier warnings of hypoglycemic and hyperglycemic events in patient in critical care, according to the results of a clinical study that GlySure presented during the World Federation of Societies of Intensive & Critical Care Medicine Congress in South Africa last week.
The GlySure system provided blood glucose concentration findings consistent with those found in traditional blood draws in a study of 24 post-surgical cardiac surgery patients in an intensive care unit, according to England-based GlySure.
"We are excited by these results," principal investigator Dr. Krishna Prasad said on behalf of the company. "A device like this would be extremely valuable in managing these kinds of patients in the ICU. The system is also easy to set up and use, which are key requirements in critical care."
Once cleared by U.S. and E.U. healthcare regulators, GlySure’s CBGM system will pave the company’s way into the $2 billion global tight-glycemic-control market, according to a press release. GlySure’s technology uses a proprietary optical fluorescence sensor that can provide "continuous glucose readings throughout the length of a patient’s stay in the ICU."
Read MassDevice.com’s Q&A with GlySure CEO Christopher Jones
The company also recently launched a multi-center CE Mark clinical trial on cardiac surgery patients, which GlySure expects to complete this fall.
